+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
CMO/CDMO Biotechnology Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)- Product Image
CMO/CDMO Biotechnology Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)- Product Image
New

CMO/CDMO Biotechnology Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • PDF Icon

    Report

  • 295 Pages
  • July 2025
  • Region: Global
  • Fairfield Market Research
  • ID: 5918341
Description Jump to:
The global CMO/CDMO biotechnology market is poised for substantial growth, driven by the increasing reliance on contract manufacturing and development services in the biopharmaceutical industry. With growing demand for cost-effective, scalable, and high-quality manufacturing solutions, the market is projected to rise from US$ 14.0 Bn in 2025 to US$ 32.0 Bn by 2032, progressing at a CAGR of 12.54% during the forecast period.

Market Insights

Contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) are playing a vital role in supporting biotechnology and biopharmaceutical companies in their drug development and production cycles. These organizations offer a wide spectrum of services, including cell-line development, bio-manufacturing, analytical testing, clinical supply, fill-finish, and packaging. As pharmaceutical companies look to streamline operations and accelerate time-to-market, outsourcing to CDMOs has become a strategic imperative.

Key Market Drivers

One of the primary growth drivers for the CMO/CDMO biotechnology market is the increasing focus on novel biologics and biosimilars. The demand for large-scale production of monoclonal antibodies, gene therapies, and recombinant proteins is propelling the need for technologically advanced and flexible contract manufacturing services. Additionally, the emergence of innovative expression systems and disposable bioreactor technologies is enhancing productivity and reducing manufacturing costs.

A rising number of biologics approvals and biosimilar launches in major markets such as the U.S. and Europe are also boosting market demand. Manufacturers are investing in capacity expansion and integrated services to serve the growing complexity and volume of biologic therapeutics. Moreover, regulatory support and the need for faster commercialization are reinforcing the trend of outsourcing drug development and manufacturing.

Business Opportunities

The expansion of biosimilar pipelines, coupled with the adoption of single-use technologies and intensified regulatory support, creates vast opportunities for market players. Companies are increasingly forming strategic partnerships and acquisitions to expand capabilities. For instance, AGC Biologics’ acquisition of Molecular Medicine S.p.A. expanded its end-to-end cell and gene therapy offerings. Similarly, Lonza’s development of the GSv9™ platform enhanced its recombinant protein manufacturing capabilities.

The mid-sized CMO/CDMO segment, offering extensive and specialized services, continues to gain traction due to its operational flexibility and growing expertise. Furthermore, the ongoing evolution of the CDMO model-focusing on integrated solutions from discovery to commercial-scale production-opens new avenues for long-term partnerships.

Regional Analysis

The U.S. remains the dominant market in North America, supported by a strong pharmaceutical manufacturing base, high merger and acquisition activity, and rapid adoption of single-use bioreactor systems. High investment in biologics production facilities and technological advancements in biomanufacturing are solidifying the region’s leadership.

In Europe, the U.K. stands out as a lucrative market with a growing number of CDMOs offering end-to-end biopharmaceutical solutions, particularly for gene and cell therapy. Manufacturers in this region focus on high-quality service offerings with a global presence.

Asia Pacific, particularly South Korea, is emerging as a key market due to its robust development services and strategic investments by global CDMOs. South Korean players like Samsung Biologics are significantly expanding cell-line development platforms and bioreactor capacities, contributing to regional market growth.

Key Players

Several key players are leading market expansion through innovation and capacity enhancement, including:

  • Patheon N.V.
  • Catalent
  • Samsung Biologics Co., Ltd
  • Lonza
  • Boehringer Ingelheim
  • AGC Biologics, Inc.
  • WuXi Biologics
  • AbbVie Inc.
  • Avid Bioservices, Inc.
  • Fujifilm Diosynth Biotechnologies
  • Rentschler Biopharma SE
  • KBI Biopharma (JSR Corporation)
  • Cytovance Biologics
  • Xpress Biologic
These companies are focusing on enhancing their service portfolios, expanding geographically, and embracing strategic collaborations to address increasing global demand for biologic development and production services.

Market Segmentation

By Service

  • Stand-alone Services
  • Integrated Services

By Product

  • Monoclonal Antibodies
  • Recombinant Proteins
  • Vaccines
  • Others

By Expression System

  • Mammalian
  • Microbial
  • Others

By Company Size

  • Small
  • Mid-sized
  • Large

By Scale of Operations

  • Clinical
  • Commercial

By Region

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia & Pacific
  • Middle East & Africa

This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global CMO/CDMO Biotechnology Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2025
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global CMO/CDMO Biotechnology Market Outlook, 2019-2032
3.1. Global CMO/CDMO Biotechnology Market Outlook, by Service, Value (US$ Bn), 2019-2032
3.1.1. Key Highlights
3.1.1.1. Stand-Alone Services
3.1.1.1.1. Cell-line development
3.1.1.1.2. Development and Bio manufacturing
3.1.1.1.3. Analytical Services
3.1.1.1.4. Fill Finish
3.1.1.1.5. Packaging
3.1.1.1.6. Clinical Supply Services
3.1.1.2. Integrated
3.2. Global CMO/CDMO Biotechnology Market Outlook, by Product, Value (US$ Bn), 2019-2032
3.2.1. Key Highlights
3.2.1.1. Monoclonal Antibodies
3.2.1.2. Antibody Fragments
3.2.1.3. Recombinant Therapeutic Proteins
3.2.1.4. Viral Vector
3.2.1.5. Cell and Gene Therapy
3.2.1.6. Vaccine
3.3. Global CMO/CDMO Biotechnology Market Outlook, by Expression System, Value (US$ Bn), 2019-2032
3.3.1. Key Highlights
3.3.1.1. Mammalian
3.3.1.2. Microbial
3.3.1.2.1. Bacteria
3.3.1.2.2. Yeast
3.4. Global CMO/CDMO Biotechnology Market Outlook, by Company Size, Value (US$ Bn), 2019-2032
3.4.1. Key Highlights
3.4.1.1. Small
3.4.1.2. Mid-Sized
3.4.1.3. Large
3.4.1.4. Very Large
3.5. Global CMO/CDMO Biotechnology Market Outlook, by Scale of Operations, Value (US$ Bn), 2019-2032
3.5.1. Key Highlights
3.5.1.1. Pre-clinical
3.5.1.2. Clinical
3.5.1.3. Commercial
3.6. Global CMO/CDMO Biotechnology Market Outlook, by Region, Value (US$ Bn), 2019-2032
3.6.1. Key Highlights
3.6.1.1. North America
3.6.1.2. Europe
3.6.1.3. Asia Pacific
3.6.1.4. Latin America
3.6.1.5. Middle East & Africa
4. North America CMO/CDMO Biotechnology Market Outlook, 2019-2032
4.1. North America CMO/CDMO Biotechnology Market Outlook, by Service, Value (US$ Bn), 2019-2032
4.1.1. Key Highlights
4.1.1.1. Stand-Alone Services
4.1.1.1.1. Cell-line development
4.1.1.1.2. Development and Bio manufacturing
4.1.1.1.3. Analytical Services
4.1.1.1.4. Fill Finish
4.1.1.1.5. Packaging
4.1.1.1.6. Clinical Supply Services
4.1.1.2. Integrated
4.2. North America CMO/CDMO Biotechnology Market Outlook, by Product, Value (US$ Bn), 2019-2032
4.2.1. Key Highlights
4.2.1.1. Monoclonal Antibodies
4.2.1.2. Antibody Fragments
4.2.1.3. Recombinant Therapeutic Proteins
4.2.1.4. Viral Vector
4.2.1.5. Cell and Gene Therapy
4.2.1.6. Vaccine
4.3. North America CMO/CDMO Biotechnology Market Outlook, by Expression System, Value (US$ Bn), 2019-2032
4.3.1. Key Highlights
4.3.1.1. Mammalian
4.3.1.2. Microbial
4.3.1.2.1. Bacteria
4.3.1.2.2. Yeast
4.4. North America CMO/CDMO Biotechnology Market Outlook, by Company Size, Value (US$ Bn), 2019-2032
4.4.1. Key Highlights
4.4.1.1. Small
4.4.1.2. Mid-Sized
4.4.1.3. Large
4.4.1.4. Very Large
4.5. North America CMO/CDMO Biotechnology Market Outlook, by Scale of Operations, Value (US$ Bn), 2019-2032
4.5.1. Key Highlights
4.5.1.1. Pre-clinical
4.5.1.2. Clinical
4.5.1.3. Commercial
4.6. North America CMO/CDMO Biotechnology Market Outlook, by Country, Value (US$ Bn), 2019-2032
4.6.1. Key Highlights
4.6.1.1. U.S. CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2019-2032
4.6.1.2. U.S. CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2019-2032
4.6.1.3. U.S. CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2019-2032
4.6.1.4. U.S. CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2019-2032
4.6.1.5. U.S. CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2019-2032
4.6.1.6. Canada CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2019-2032
4.6.1.7. Canada CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2019-2032
4.6.1.8. Canada CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2019-2032
4.6.1.9. Canada CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2019-2032
4.6.1.10. Canada CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2019-2032
4.6.2. BPS Analysis/Market Attractiveness Analysis
5. Europe CMO/CDMO Biotechnology Market Outlook, 2019-2032
5.1. Europe CMO/CDMO Biotechnology Market Outlook, by Service, Value (US$ Bn), 2019-2032
5.1.1. Key Highlights
5.1.1.1. Stand-Alone Services
5.1.1.1.1. Cell-line development
5.1.1.1.2. Development and Bio manufacturing
5.1.1.1.3. Analytical Services
5.1.1.1.4. Fill Finish
5.1.1.1.5. Packaging
5.1.1.1.6. Clinical Supply Services
5.1.1.2. Integrated
5.2. Europe CMO/CDMO Biotechnology Market Outlook, by Product, Value (US$ Bn), 2019-2032
5.2.1. Key Highlights
5.2.1.1. Monoclonal Antibodies
5.2.1.2. Antibody Fragments
5.2.1.3. Recombinant Therapeutic Proteins
5.2.1.4. Viral Vector
5.2.1.5. Cell and Gene Therapy
5.2.1.6. Vaccine
5.3. Europe CMO/CDMO Biotechnology Market Outlook, by Expression System, Value (US$ Bn), 2019-2032
5.3.1. Key Highlights
5.3.1.1. Mammalian
5.3.1.2. Microbial
5.3.1.2.1. Bacteria
5.3.1.2.2. Yeast
5.4. Europe CMO/CDMO Biotechnology Market Outlook, by Company Size, Value (US$ Bn), 2019-2032
5.4.1. Key Highlights
5.4.1.1. Small
5.4.1.2. Mid-Sized
5.4.1.3. Large
5.4.1.4. Very Large
5.5. Europe CMO/CDMO Biotechnology Market Outlook, by Scale of Operations, Value (US$ Bn), 2019-2032
5.5.1. Key Highlights
5.5.1.1. Pre-clinical
5.5.1.2. Clinical
5.5.1.3. Commercial
5.6. Europe CMO/CDMO Biotechnology Market Outlook, by Country, Value (US$ Bn), 2019-2032
5.6.1. Key Highlights
5.6.1.1. Germany CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2019-2032
5.6.1.2. Germany CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2019-2032
5.6.1.3. Germany CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2019-2032
5.6.1.4. Germany CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2019-2032
5.6.1.5. Germany CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2019-2032
5.6.1.6. U.K. CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2019-2032
5.6.1.7. U.K. CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2019-2032
5.6.1.8. U.K. CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2019-2032
5.6.1.9. U.K. CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2019-2032
5.6.1.10. U.K. CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2019-2032
5.6.1.11. France CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2019-2032
5.6.1.12. France CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2019-2032
5.6.1.13. France CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2019-2032
5.6.1.14. France CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2019-2032
5.6.1.15. France CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2019-2032
5.6.1.16. Italy CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2019-2032
5.6.1.17. Italy CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2019-2032
5.6.1.18. Italy CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2019-2032
5.6.1.19. Italy CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2019-2032
5.6.1.20. Italy CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2019-2032
5.6.1.21. Turkey CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2019-2032
5.6.1.22. Turkey CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2019-2032
5.6.1.23. Turkey CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2019-2032
5.6.1.24. Turkey CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2019-2032
5.6.1.25. Turkey CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2019-2032
5.6.1.26. Russia CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2019-2032
5.6.1.27. Russia CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2019-2032
5.6.1.28. Russia CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2019-2032
5.6.1.29. Russia CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2019-2032
5.6.1.30. Russia CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2019-2032
5.6.1.31. Rest of Europe CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2019-2032
5.6.1.32. Rest of Europe CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2019-2032
5.6.1.33. Rest of Europe CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2019-2032
5.6.1.34. Rest of Europe CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2019-2032
5.6.1.35. Rest of Europe CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2019-2032
5.6.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific CMO/CDMO Biotechnology Market Outlook, 2019-2032
6.1. Asia Pacific CMO/CDMO Biotechnology Market Outlook, by Service, Value (US$ Bn), 2019-2032
6.1.1. Key Highlights
6.1.1.1. Instruments
6.1.1.1.1. Fully CMO/CDMO Biotechnology
6.1.1.1.2. Semi-CMO/CDMO Biotechnology
6.1.1.2. Consumables
6.2. Asia Pacific CMO/CDMO Biotechnology Market Outlook, by Product, Value (US$ Bn), 2019-2032
6.2.1. Key Highlights
6.2.1.1. Stand-Alone Services
6.2.1.1.1. Cell-line development
6.2.1.1.2. Development and Bio manufacturing
6.2.1.1.3. Analytical Services
6.2.1.1.4. Fill Finish
6.2.1.1.5. Packaging
6.2.1.1.6. Clinical Supply Services
6.2.1.2. Integrated
6.3. Asia Pacific CMO/CDMO Biotechnology Market Outlook, by Product, Value (US$ Bn), 2019-2032
6.3.1. Key Highlights
6.3.1.1. Monoclonal Antibodies
6.3.1.2. Antibody Fragments
6.3.1.3. Recombinant Therapeutic Proteins
6.3.1.4. Viral Vector
6.3.1.5. Cell and Gene Therapy
6.3.1.6. Vaccine
6.4. Asia Pacific CMO/CDMO Biotechnology Market Outlook, by Expression System, Value (US$ Bn), 2019-2032
6.4.1. Key Highlights
6.4.1.1. Mammalian
6.4.1.2. Microbial
6.4.1.2.1. Bacteria
6.4.1.2.2. Yeast
6.5. Asia Pacific CMO/CDMO Biotechnology Market Outlook, by Company Size, Value (US$ Bn), 2019-2032
6.5.1. Key Highlights
6.5.1.1. Small
6.5.1.2. Mid-Sized
6.5.1.3. Large
6.5.1.4. Very Large
6.6. Asia Pacific CMO/CDMO Biotechnology Market Outlook, by Scale of Operations, Value (US$ Bn), 2019-2032
6.6.1. Key Highlights
6.6.1.1. Pre-clinical
6.6.1.2. Clinical
6.6.1.3. Commercial
6.7. Asia Pacific CMO/CDMO Biotechnology Market Outlook, by Country, Value (US$ Bn), 2019-2032
6.7.1. Key Highlights
6.7.1.1. China CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2019-2032
6.7.1.2. China CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2019-2032
6.7.1.3. China CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2019-2032
6.7.1.4. China CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2019-2032
6.7.1.5. China CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2019-2032
6.7.1.6. Japan CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2019-2032
6.7.1.7. Japan CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2019-2032
6.7.1.8. Japan CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2019-2032
6.7.1.9. Japan CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2019-2032
6.7.1.10. Japan CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2019-2032
6.7.1.11. South Korea CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2019-2032
6.7.1.12. South Korea CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2019-2032
6.7.1.13. South Korea CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2019-2032
6.7.1.14. South Korea CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2019-2032
6.7.1.15. South Korea CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2019-2032
6.7.1.16. India CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2019-2032
6.7.1.17. India CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2019-2032
6.7.1.18. India CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2019-2032
6.7.1.19. India CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2019-2032
6.7.1.20. India CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2019-2032
6.7.1.21. Southeast Asia CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2019-2032
6.7.1.22. Southeast Asia CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2019-2032
6.7.1.23. Southeast Asia CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2019-2032
6.7.1.24. Southeast Asia CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2019-2032
6.7.1.25. Southeast Asia CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2019-2032
6.7.1.26. Rest of Asia Pacific CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2019-2032
6.7.1.27. Rest of Asia Pacific CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2019-2032
6.7.1.28. Rest of Asia Pacific CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2019-2032
6.7.1.29. Rest of Asia Pacific CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2019-2032
6.7.1.30. Rest of Asia Pacific CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2019-2032
6.7.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America CMO/CDMO Biotechnology Market Outlook, 2019-2032
7.1. Latin America CMO/CDMO Biotechnology Market Outlook, by Service, Value (US$ Bn), 2019-2032
7.1.1. Key Highlights
7.1.1.1. Stand-Alone Services
7.1.1.1.1. Cell-line development
7.1.1.1.2. Development and Bio manufacturing
7.1.1.1.3. Analytical Services
7.1.1.1.4. Fill Finish
7.1.1.1.5. Packaging
7.1.1.1.6. Clinical Supply Services
7.1.1.2. Integrated
7.2. Latin America CMO/CDMO Biotechnology Market Outlook, by Product, Value (US$ Bn), 2019-2032
7.2.1. Key Highlights
7.2.1.1. Monoclonal Antibodies
7.2.1.2. Antibody Fragments
7.2.1.3. Recombinant Therapeutic Proteins
7.2.1.4. Viral Vector
7.2.1.5. Cell and Gene Therapy
7.2.1.6. Vaccine
7.3. Latin America CMO/CDMO Biotechnology Market Outlook, by Expression System, Value (US$ Bn), 2019-2032
7.3.1. Key Highlights
7.3.1.1. Mammalian
7.3.1.2. Microbial
7.3.1.2.1. Bacteria
7.3.1.2.2. Yeast
7.4. Latin America CMO/CDMO Biotechnology Market Outlook, by Company Size, Value (US$ Bn), 2019-2032
7.4.1. Key Highlights
7.4.1.1. Small
7.4.1.2. Mid-Sized
7.4.1.3. Large
7.4.1.4. Very Large
7.5. Latin America CMO/CDMO Biotechnology Market Outlook, by Scale of Operations, Value (US$ Bn), 2019-2032
7.5.1. Key Highlights
7.5.1.1. Pre-clinical
7.5.1.2. Clinical
7.5.1.3. Commercial
7.6. Latin America CMO/CDMO Biotechnology Market Outlook, by Country, Value (US$ Bn), 2019-2032
7.6.1. Key Highlights
7.6.1.1. Brazil CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2019-2032
7.6.1.2. Brazil CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2019-2032
7.6.1.3. Brazil CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2019-2032
7.6.1.4. Brazil CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2019-2032
7.6.1.5. Brazil CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2019-2032
7.6.1.6. Mexico CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2019-2032
7.6.1.7. Mexico CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2019-2032
7.6.1.8. Mexico CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2019-2032
7.6.1.9. Mexico CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2019-2032
7.6.1.10. Mexico CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2019-2032
7.6.1.11. Argentina CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2019-2032
7.6.1.12. Argentina CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2019-2032
7.6.1.13. Argentina CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2019-2032
7.6.1.14. Argentina CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2019-2032
7.6.1.15. Argentina CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2019-2032
7.6.1.16. Rest of Latin America CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2019-2032
7.6.1.17. Rest of Latin America CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2019-2032
7.6.1.18. Rest of Latin America CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2019-2032
7.6.1.19. Rest of Latin America CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2019-2032
7.6.1.20. Rest of Latin America CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2019-2032
7.6.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa CMO/CDMO Biotechnology Market Outlook, 2019-2032
8.1. Middle East & Africa CMO/CDMO Biotechnology Market Outlook, by Service, Value (US$ Bn), 2019-2032
8.1.1. Key Highlights
8.1.1.1. Instruments
8.1.1.1.1. Fully CMO/CDMO Biotechnology
8.1.1.1.2. Semi-CMO/CDMO Biotechnology
8.1.1.2. Consumables
8.2. Middle East & Africa CMO/CDMO Biotechnology Market Outlook, by Product, Value (US$ Bn), 2019-2032
8.2.1. Key Highlights
8.2.1.1. Stand-Alone Services
8.2.1.1.1. Cell-line development
8.2.1.1.2. Development and Bio manufacturing
8.2.1.1.3. Analytical Services
8.2.1.1.4. Fill Finish
8.2.1.1.5. Packaging
8.2.1.1.6. Clinical Supply Services
8.2.1.2. Integrated
8.3. Middle East & Africa CMO/CDMO Biotechnology Market Outlook, by Product, Value (US$ Bn), 2019-2032
8.3.1. Key Highlights
8.3.1.1. Monoclonal Antibodies
8.3.1.2. Antibody Fragments
8.3.1.3. Recombinant Therapeutic Proteins
8.3.1.4. Viral Vector
8.3.1.5. Cell and Gene Therapy
8.3.1.6. Vaccine
8.4. Middle East & Africa CMO/CDMO Biotechnology Market Outlook, by Expression System, Value (US$ Bn), 2019-2032
8.4.1. Key Highlights
8.4.1.1. Mammalian
8.4.1.2. Microbial
8.4.1.2.1. Bacteria
8.4.1.2.2. Yeast
8.5. Middle East & Africa CMO/CDMO Biotechnology Market Outlook, by Company Size, Value (US$ Bn), 2019-2032
8.5.1. Key Highlights
8.5.1.1. Small
8.5.1.2. Mid-Sized
8.5.1.3. Large
8.5.1.4. Very Large
8.6. Middle East & Africa CMO/CDMO Biotechnology Market Outlook, by Scale of Operations, Value (US$ Bn), 2019-2032
8.6.1. Key Highlights
8.6.1.1. Pre-clinical
8.6.1.2. Clinical
8.6.1.3. Commercial
8.7. Middle East & Africa CMO/CDMO Biotechnology Market Outlook, by Country, Value (US$ Bn), 2019-2032
8.7.1. Key Highlights
8.7.1.1. GCC CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2019-2032
8.7.1.2. GCC CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2019-2032
8.7.1.3. GCC CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2019-2032
8.7.1.4. GCC CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2019-2032
8.7.1.5. GCC CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2019-2032
8.7.1.6. South Africa CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2019-2032
8.7.1.7. South Africa CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2019-2032
8.7.1.8. South Africa CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2019-2032
8.7.1.9. South Africa CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2019-2032
8.7.1.10. South Africa CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2019-2032
8.7.1.11. Egypt CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2019-2032
8.7.1.12. Egypt CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2019-2032
8.7.1.13. Egypt CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2019-2032
8.7.1.14. Egypt CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2019-2032
8.7.1.15. Egypt CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2019-2032
8.7.1.16. Nigeria CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2019-2032
8.7.1.17. Nigeria CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2019-2032
8.7.1.18. Nigeria CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2019-2032
8.7.1.19. Nigeria CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2019-2032
8.7.1.20. Nigeria CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2019-2032
8.7.1.21. Rest of Middle East & Africa CMO/CDMO Biotechnology Market by Service, Value (US$ Bn), 2019-2032
8.7.1.22. Rest of Middle East & Africa CMO/CDMO Biotechnology Market by Product, Value (US$ Bn), 2019-2032
8.7.1.23. Rest of Middle East & Africa CMO/CDMO Biotechnology Market by Expression System, Value (US$ Bn), 2019-2032
8.7.1.24. Rest of Middle East & Africa CMO/CDMO Biotechnology Market by Company Size, Value (US$ Bn), 2019-2032
8.7.1.25. Rest of Middle East & Africa CMO/CDMO Biotechnology Market by Scale of Operation, Value (US$ Bn), 2019-2032
8.7.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Service vs Product Heatmap
9.2. Manufacturer vs Product Heatmap
9.3. Company Market Share Analysis, 2025
9.4. Competitive Dashboard
9.5. Company Profiles
9.5.1. Patheon N.V.
9.5.1.1. Company Overview
9.5.1.2. Service Portfolio
9.5.1.3. Financial Overview
9.5.1.4. Business Strategies and Development
9.5.2. Catalent
9.5.2.1. Company Overview
9.5.2.2. Service Portfolio
9.5.2.3. Financial Overview
9.5.2.4. Business Strategies and Development
9.5.3. Samsung Biologics Co., Ltd
9.5.3.1. Company Overview
9.5.3.2. Service Portfolio
9.5.3.3. Financial Overview
9.5.3.4. Business Strategies and Development
9.5.4. Lonza.
9.5.4.1. Company Overview
9.5.4.2. Service Portfolio
9.5.4.3. Financial Overview
9.5.4.4. Business Strategies and Development
9.5.5. Boehringer Ingelheim
9.5.5.1. Company Overview
9.5.5.2. Service Portfolio
9.5.5.3. Financial Overview
9.5.5.4. Business Strategies and Development
9.5.6. Samsung BioLogics
9.5.6.1. Company Overview
9.5.6.2. Service Portfolio
9.5.6.3. Financial Overview
9.5.6.4. Business Strategies and Development
9.5.7. AGC Biologics, Inc.
9.5.7.1. Company Overview
9.5.7.2. Service Portfolio
9.5.7.3. Financial Overview
9.5.7.4. Business Strategies and Development
9.5.8. WuXi Biologics
9.5.8.1. Company Overview
9.5.8.2. Service Portfolio
9.5.8.3. Financial Overview
9.5.8.4. Business Strategies and Development
9.5.9. AbbVie Inc
9.5.9.1. Company Overview
9.5.9.2. Service Portfolio
9.5.9.3. Financial Overview
9.5.9.4. Business Strategies and Development
9.5.10. Avid Bioservices, Inc.
9.5.10.1. Company Overview
9.5.10.2. Service Portfolio
9.5.10.3. Financial Overview
9.5.10.4. Business Strategies and Development
9.5.11. Fujifilm Diosynth Biotechnologies
9.5.11.1. Company Overview
9.5.11.2. Service Portfolio
9.5.11.3. Financial Overview
9.5.11.4. Business Strategies and Development
9.5.12. Xpress Biologic
9.5.12.1. Company Overview
9.5.12.2. Service Portfolio
9.5.12.3. Financial Overview
9.5.12.4. Business Strategies and Development
9.5.13. Rentschler Biopharma SE
9.5.13.1. Company Overview
9.5.13.2. Service Portfolio
9.5.13.3. Financial Overview
9.5.13.4. Business Strategies and Development
9.5.14. KBI Biopharma (JSR Corporation)
9.5.14.1. Company Overview
9.5.14.2. Service Portfolio
9.5.14.3. Financial Overview
9.5.14.4. Business Strategies and Development
9.5.14.5. Business Strategies and Development
9.5.15. Cytovance Biologics
9.5.15.1. Company Overview
9.5.15.2. Service Portfolio
9.5.15.3. Financial Overview
9.5.15.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned

  • Patheon N.V.
  • Catalent
  • Samsung Biologics Co., Ltd
  • Lonza.
  • Boehringer Ingelheim
  • Samsung BioLogics
  • AGC Biologics, Inc.
  • WuXi Biologics
  • AbbVie Inc
  • Avid Bioservices, Inc.
  • Fujifilm Diosynth Biotechnologies
  • Xpress Biologic
  • Rentschler Biopharma SE
  • KBI Biopharma (JSR Corporation)
  • Cytovance Biologics

Related Topics

Related Reports

Small Molecule CMO/CDMO Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Small Molecule CMO/CDMO Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 157 Pages
  • Global
From
Small Molecule CMO/CDMO Market Report 2025 - Product Image

Small Molecule CMO/CDMO Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Pharmaceutical Contract Development and Manufacturing Organization (CDMO) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Pharmaceutical Contract Development and Manufacturing Organization (CDMO) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 317 Pages
  • Global
From
Healthcare CMO Market: Analysis By Type, Region Size, Trends and Forecast up to 2029 - Product Image

Healthcare CMO Market: Analysis By Type, Region Size, Trends and Forecast up to 2029

  • Report
  • 144 Pages
  • Global
From
Pharmaceutical Contract Development and Manufacturing Organization (CMO) Market Report 2025 - Product Image

Pharmaceutical Contract Development and Manufacturing Organization (CMO) Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.